{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:22:23Z","timestamp":1791598943184,"version":"4.3.4"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,2,2]],"date-time":"2009-02-02T00:00:00Z","timestamp":1233532800000},"content-version":"vor","delay-in-days":2499,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:p>\n                    <jats:list list-type=\"explicit-label\">\n                      <jats:list-item>\n                        <jats:p>\n                          Experiments were carried out in conscious, chronically instrumented, male, Sprague\u2010Dawley rats to delineate the regional haemodynamic effects of the putative endogenous cannabinoid, anandamide, (0.075\u2003\u2013\u20033\u2003mg\u2003kg\n                          <jats:sup>\u22121<\/jats:sup>\n                          ), and to dissect some of the mechanisms involved.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>At all doses of anandamide, there was a significant, short\u2010lived increase in mean arterial blood pressure associated with vasoconstriction in renal, mesenteric and hindquarters vascular beds.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          The higher doses (2.5 and 3\u2003mg\u2003kg\n                          <jats:sup>\u22121<\/jats:sup>\n                          ), caused an initial, marked bradycardia accompanied, in some animals, by a fall in arterial blood pressure which preceded the hypertension. In addition, after the higher doses of anandamide, the hindquarters vasoconstriction was followed by vasodilatation.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          Although some of the effects described above resembled those of 5\u2010HT (25\u2003\u03bcg\u2003kg\n                          <jats:sup>\u22121<\/jats:sup>\n                          ), the bradycardia and hypotensive actions of the latter were abolished by the 5HT\n                          <jats:sub>3<\/jats:sub>\n                          \u2010receptor antagonist, azasetron, whereas those of anandamide were generally unaffected.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          None of the cardiovascular actions of anandamide were influenced by the CB\n                          <jats:sub>1<\/jats:sub>\n                          \u2010receptor antagonist, AM 251, but its bradycardic effect was sensitive to atropine, and its hindquarters vasodilator action was suppressed by the \u03b2\n                          <jats:sub>2<\/jats:sub>\n                          \u2010adrenoceptor antagonist, ICI 118551.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>The results differ, in several aspects, from those previously reported in anaesthetized animals, and underscore the important impact anaesthesia can have on responses to anandamide.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>British Journal of Pharmacology<\/jats:italic>\n                    (2002)\n                    <jats:bold>135<\/jats:bold>\n                    , 1889\u20131896; doi:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0704649\">10.1038\/sj.bjp.0704649<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1038\/sj.bjp.0704649","type":"journal-article","created":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T16:51:22Z","timestamp":1106931082000},"page":"1889-1896","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Complex regional haemodynamic effects of anandamide in conscious rats"],"prefix":"10.1111","volume":"135","author":[{"given":"S M","family":"Gardiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J E","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P A","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,2,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198305000-00013"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90443-T"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2001.280.1.G14"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb09066.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb16405.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704100"},{"key":"e_1_2_6_8_1","article-title":"Effects of the cannabinoid receptor antagonist, AM 251, on the cardiovascular responses to the cannabinoid receptor agonist, WIN 55212\u20102, and to anandamide, in conscious rats","author":"GARDINER S.M.","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"e_1_2_6_9_1","article-title":"\u03b22\u2010adrenoceptor involvement in the hindquarters vasodilator effects of WIN 55212\u20102, HU 210 and anandamide in conscious Sprague\u2010Dawley rats","author":"GARDINER S.M.","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00279-8"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00690-5"},{"key":"e_1_2_6_12_1","first-page":"27","article-title":"Endocannabinoids and vascular function","volume":"294","author":"HILLARD C.J.","year":"2000","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-3084(00)00194-8"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.29.5.1204"},{"key":"e_1_2_6_15_1","first-page":"172P","article-title":"Cardiovascular effects on anandamide and of 5\u2010HT in the absence and presence of the 5HT3\u2010receptor antagonist, azasetron, in conscious rats","volume":"131","author":"LIU B.","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1838(96)00109-9"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00649-9"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(00)01482-6"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15683.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.28.4.682"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00181-J"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702259"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01112-8"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb09034.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1991.sp018433"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/22761"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0704649","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0704649","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0704649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T21:08:50Z","timestamp":1697490530000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0704649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1038\/sj.bjp.0704649"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0704649","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]},"assertion":[{"value":"2009-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}